Free Trial
→ 7 market signals flashing red right now (From American Alternative) (Ad)tc pixel

Carlsmed (NASDAQ:CARL) Now Covered by Weiss Ratings

Written by MarketBeat
October 17, 2025

Key Points

  • Weiss Ratings has initiated coverage on Carlsmed (NASDAQ:CARL) with a "sell (e)" rating, indicating a cautious outlook for the stock.
  • Carlsmed's stock price increased by 1.7% to $13.88, with trading volume being notably lower than its average.
  • In its recent quarterly earnings, Carlsmed reported an EPS of ($1.47), exceeding estimates, and recorded revenue of $12.08 million, surpassing expectations as well.
  • Interested in Carlsmed? Here are five stocks we like better.

Analysts at Weiss Ratings assumed coverage on shares of Carlsmed (NASDAQ:CARL - Get Free Report) in a research note issued on Thursday,Weiss Ratings reports. The firm set a "sell (e)" rating on the stock.

Carlsmed Stock Up 1.7%

CARL traded up $0.23 during midday trading on Thursday, hitting $13.88. 16,805 shares of the company were exchanged, compared to its average volume of 154,433. Carlsmed has a 1-year low of $11.81 and a 1-year high of $16.20.

Carlsmed (NASDAQ:CARL - Get Free Report) last announced its quarterly earnings data on Thursday, August 28th. The company reported ($1.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.52) by $0.05. The business had revenue of $12.08 million during the quarter, compared to analyst estimates of $11.98 million.

About Carlsmed

(Get Free Report)

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Carlsmed Right Now?

Before you consider Carlsmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carlsmed wasn't on the list.

While Carlsmed currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.